Rapid Drug Susceptibility Testing with a Molecular Beacon Assay Is Associated with Earlier Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in California
Rapid Drug Susceptibility Testing with a Molecular Beacon Assay Is Associated with Earlier Diagnosis and Treatment of Multidrug-Resistant Tuberculosis in California
复制标题
DOI：
10.1128/jcm.01236-10
复制
发表时间：
2010-10-01
影响因子：
9.4
通讯作者：
Flood, Jennifer
中科院分区：
文献类型：
--
作者：
Banerjee, Ritu;Allen, Jennifer;Flood, Jennifer
为了评估检测耐多药结核病（MDR TB）的分子信标（MB）检测的临床影响，我们回顾性分析了2004年至2007年期间127例接受和未接受MB检测的MDR TB患者的记录。MB检测试剂盒的使用缩短了检测和治疗MDR TB的时间。
To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records of 127 MDR TB patients with and without MB testing between 2004 and 2007. Use of the MB assay reduced the time to detection and treatment of MDR TB.